Atea/AVIR

$4.45

3.24%
-
1D1W1MYTD1YMAX

About Atea

Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The Company is engaged in developing its product candidate, bemnifosbuvir, for the treatment of coronavirus disease 2019 (COVID-19), and its variants. The Company is also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV). The bemnifosbuvir (AT-527) for COVID-19 addresses key limitations of current therapies and explores combination therapy for specific patient populations. Bemnifosbuvir is an investigational, orally administered, non-mutagenic, non-teratogenic, direct-acting antiviral agent. The Company's SUNRISE-3 is designed to evaluate bemnifosbuvir as monotherapy but also explores the effect of combination therapy in a smaller sub-set of patients who receive an antiviral drug along with bemnifosbuvir.

Ticker

AVIR

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Jean-Pierre Sommadossi

Employees

74

Headquarters

Boston, United States

Atea Metrics

BasicAdvanced
$359.61M
Market cap
-
P/E ratio
-$1.57
EPS
0.17
Beta
-
Dividend rate

What the Analysts think about Atea

Analyst Ratings

Majority rating from 4 analysts.
Sell

Price Targets

Average projection from 2 analysts.
21.35% downside
High $5.00
Low $2.00
$4.45
Current price
$3.50
Average price target

Atea Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$0
-
Net income
$-33.1M
17.79%
Profit margin
0%
-

Atea Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 5.37%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.43
-$0.34
-$0.40
-$0.47
-
Expected
-$0.48
-$0.47
-$0.48
-$0.50
-$0.60
Surprise
-9.95%
-27.66%
-16.08%
-5.37%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Atea stock

Buy or sell Atea stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing